Nanoparticle medicine company Nanoform said that proof of concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform’s CESS technology can deliver to its drug development projects.   The two parties executed a master services agreement (MSA) to initiate projects in the pre-clinical early development space with the aim of solving the ever-growing challenge of poor bioavailability and solubility in new drug candidates—a leading cause of drug development failur...